International Clinical Trial: A Prospective, Single-arm Clinical Study of Immune-targeted Therapy Combined With Lysogenic HSV Virus for the Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma

Geneva, May 7 -- International Clinical Trials Registry received information related to the study (ChiCTR2600123934) titled 'A Prospective, Single-arm Clinical Study of Immune-targeted Therapy Combined With Lysogenic HSV Virus for the Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma' on May 1.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: West China Hospital of Sichuan University

Condition: head and neck cancer

Intervention: Dose Escalation Phase 1 Group:Oncolytic HSV virus 10^6 pfu/mL, 1-4 mL, injected twice with a 2-week interval between doses Dose Escalation Phase 2 Group:Oncolytic HSV virus 10^8 pfu/mL, 1-4 mL, injected twice with a 2-week interval between doses Phase...